Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer.
Bevacizumab
HER2-positive
Metastatic breast cancer
Paclitaxel
Salvage therapy
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
16
04
2021
accepted:
23
07
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Although various first- to third-line HER2-targeted therapies have been established, the optimal sequence after third-line therapy has not been determined yet. Here, we describe seven patients with HER2-positive metastatic breast cancer who underwent bevacizumab (BV) and paclitaxel (PTX) combination therapy after several HER2-targeted therapies. Re-biopsy of metastatic sites was performed on four patients during the treatment prior to BV + PTX; three patients presented the same HER2-positive status as that of the primary tumor and two of whom achieved partial response. Four of seven patients achieved partial response and a 10-month median progression-free survival. Therefore, bevacizumab combined with paclitaxel is potentially effective in the treatment of HER2-positive metastatic breast cancer, if standard HER2-targeted therapy fails.
Identifiants
pubmed: 34567947
doi: 10.1007/s13691-021-00504-z
pii: 504
pmc: PMC8421475
doi:
Types de publication
Case Reports
Langues
eng
Pagination
329-333Informations de copyright
© The Japan Society of Clinical Oncology 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Breast Cancer Res. 2020 Nov 30;22(1):131
pubmed: 33256829
Oxf Med Case Reports. 2015 Apr 10;2015(4):254-7
pubmed: 26634139
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Breast Cancer Res Treat. 2013 Jun;139(2):403-10
pubmed: 23645007
Oncologist. 2012;17(4):469-75
pubmed: 22467666
Gan To Kagaku Ryoho. 2017 Jul;44(7):591-593
pubmed: 28790263
J Clin Oncol. 2013 May 10;31(14):1719-25
pubmed: 23569311